Changes in antioxidant status and lipid peroxidation in Nigerian patients with prostate carcinoma

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 9, 2009, Pages 526-532

  Akinloye, Oluyemi ^a   Adaramoye, Oluwatosin ^b   Kareem, Olatunji ^c  

^a Ladoke Akintola University   (Nigeria)

^b UNIVERSITY OF IBADAN   (Nigeria)

^c UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Antioxidant; Lipid peroxidation; Nigerian; Prostate cancer; Prostate specific antigen

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; ASCORBIC ACID; BILIRUBIN; CATALASE; GLUTATHIONE; PROSTATE SPECIFIC ANTIGEN; SUPEROXIDE DISMUTASE; URIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER GRADING; CANCER PATIENT; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NIGERIA; PROSTATE CARCINOMA; URIC ACID BLOOD LEVEL; VITAMIN BLOOD LEVEL;

EID: 70349876469     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.759     Document Type: Article

References (60)

1. World Health Organization. Diet, nutrition, and the prevention of chronic diseases: report of a joint WHO/FAO expert consultation, 2003.
2. Landis S, Bolden S, Wingo P. Cancer Statistics, 1999. CA Cancer J Clin. 1999; 49: 28-41.
3. Weisman K, Larijani G, Goldstein M, et al. Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men. Pharmacotherapy. 2000; 20: 383-386. (Pubitemid 30198842)
4. Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999; 8: 29-36. (Pubitemid 29278945)
5. Catalona W, Smith D, Ornstein D. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997; 277: 1452-1455.
6. Walter R. A public service of the Centre for Acadiana Genetics and Hereditary. Health Care. 2004; 10: 3-5.
7. Walsh GL, Gokaslan ZL, McCutcheon IE, et al. Anterior approaches to the thoracic spine in patients with cancer: indications and results. Ann Thorac Surg. 1997; 64: 1611-1618. (Pubitemid 28066527)
8. Yancik R. Integration of aging and cancer research in geriatric medicine. J Gerontol A Biol Sci Med Sci. 1997; 52A: M329-M332. (Pubitemid 28006998)
9. Jemal A, Murray T, Ward E, et al. Cancer Statistics 2005. CA cancer J Chin. 2005; 55: 10-30.
10. Hudson TS, Hartle DK, Hursting SD, et al. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res. 2007; 67: 8396-8405.
11. Schwarz S, Obermuller-Jevic UC, Hellmis E, et al. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr. 2008; 138: 49-53.
12. Neuhouser ML. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer. 2004; 50: 1-7. (Pubitemid 39587599)
13. Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol. 2004; 92: 297-305. (Pubitemid 40136584)
14. Ozasa K, Nakao M, Watanabe Y, et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci. 2004; 95: 65-71. (Pubitemid 38208409)
15. Hahm E, Singh SV. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther. 2007; 6: 2686-2695. (Pubitemid 350058149)
16. Roy S, Kaur M, Agarwal C, et al. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther. 2007; 6: 2696-2707. (Pubitemid 350058150)
17. Deep G, Oberlies NH, Kroll DJ, et al. Isosilybin B and isosilybin A inhibit growth, induce G1 artest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis. 2007; 28: 1533-1542. (Pubitemid 47241803)
18. Ahmad KA, Harris NH, Johnson AD, et al. Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Mol Cancer Ther. 2007; 6: 1006-1012.
19. Miyake H, Hara I, Kamidono S, et al. Oxidative DNA damage in patients with prostate cancer and its response to treatment. J Urol. 2004;171:1533-1536. (Pubitemid 38365412)
20. McCord JM, Fridovich I. Superoxide dismutase, an enzymatic function for erythrocuperin. J Biol Chem. 1969; 244: 6049-6055.
21. Aebi H. Catalase estimation. In: Bergmeyer HV, ed. Methods of Enzymatic Analysis. New York, Verlag Chemic, 1974: 673-684.
22. Moron MA, Depierre JW, Mannervick B. Levels of glutathione, glutathione reductase and glutathione-S- transferase activities in rat lung and liver. Biochem Biophy Acta. 1979; 582: 67-78.
23. Mohun AF, Cook IJ. Simple methods for measuring serum level of the glutamic oxaloacetic and glutamic pyruvic transaminases in routine laboratories. J Clin Pathol. 1957; 10: 394-399.
24. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxaloacetic and pyruvic transaminases. Am J Clin Pathol. 1957; 28: 56-63.
25. Williamson T. A comparison between the phosphastrate and phenyl phosphate methods of alkaline phosphatase assay. Med Lab Technol. 1972; 29: 182-187.
26. Lowry OH, Rosenbrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193: 265-275.
27. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978; 30: 302-310.
28. Rutkowski RB, DeBaare L. An ultra-micro colorimetric method for determination of total and direct serum bilirubin. Clin Chem. 1966; 12: 432-438.
29. Bergman F, Shabtay D. Studies on uric acid and related compounds. I. Quantitative determination of uric acid in biological fluids. J Biol Chem. 1954; 211: 149-162.
30. Sauberlich HE. Human requirements and needs. Vitamin C status: methods and findings. Ann N Y Acad Sci. 1975; 258: 438-450.
31. Meshali MM, Nightingale CH. Improved method for microdetermination of plasma vitamin E in laboratory rats. J Pharm Sci. 1974; 63: 1084-1086.
32. Langseth L. Oxidants, antioxidants and disease prevention. Belgium, International Life Science Institute, 1996.
33. Kelly JM, Vaage AS, Milligan LP, et al. In vitro ouabain-sensitive respiration and protein synthesis in rumen epithelial papillae of Hereford steers fed either timothy hay or timothy hay supplemented with cracked corn once daily. J Anim Sci. 1995; 73: 3775-3784.
34. Monteiro HP Stem A. Redox modulation of tyrosine phosphorylation dependent signal transduction pathways. Free Radic Biol Med. 1996; 21: 323-333. (Pubitemid 26271722)
35. Manna SK, Zhang HJ, Yan T, et al. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kB and activated protein-1. J Biol Chem. 1998; 273: 13245-13254. (Pubitemid 28246897)
36. Nutton-Persson AC, Szweda LI. Modulation of mitochondrial function by hydrogen peroxide. J Biol Chem. 2001; 276: 23357-23361. (Pubitemid 37410719)
37. Meister A, Anderson ME. Glutathione. Annu Rev Biochem. 1983; 52: 711-760.
38. Lundberg M, Johansson C, Chandra J, et al. Cloning and expression of a novel human glutaredoxin (Grx2) with mitochondrial and nuclear isoforms. J Biol Chem. 2001; 276: 26269-26275. (Pubitemid 37412842)
39. Holmgren A. Thioredoxin. Annu Rev Biochem. 1985; 54: 237-271.
40. Oberley TD. Oxidative Damage and Cancer. Am J Path. 2002; 60: 403-408.
41. Oberley TO, Oberley LW. Antioxidant enzyme levels in cancer. Histol Histopathol. 1997; 12: 525-535.
42. Oberley TD, Sempf JM, Oberley MJ, et al. Immunogold analysis of antioxidant enzymes in human renal carcinoma. Virchows Arch. 1994; 424: 155-164.
43. Coursin DB, Cihla HP, Sempf JM, et al. An immunohistochemical analysis of antioxidant and glutathione S-transferase enzyme levels in normal and neoplastic human lung. Histol Histopathol. 1996; 11: 851-860.
44. Bostwick D, Alexander E, Singh R, et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer. 2000; 89: 123-134. (Pubitemid 30451282)
45. Kotrikadze N, Alibegashvili M, Zibzibadze M, et al. Activity and content of antioxidant enzymes in prostate tumors. Exp Oncol. 2008; 30: 244-247.
46. Oberley TD, Zhong W, Szweda LI, et al. Localization of antioxidant enzymes and oxidative damage products in normal and malignant prostate epithelium. Prostate. 2000; 44: 144-155. (Pubitemid 30419189)
47. Ambrosone CB, Freudenheim JL, Thompson PA, et al. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res. 1999; 59: 602-606. (Pubitemid 29076057)
48. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979; 59: 527-605.
49. Okamoto K, Toyokuni S, Uchida K, et al. Formation of 8-hydroxy-2- deoxyguanosine and 4-hydroxy-2-nonenal-modified proteins in human renal-cell carcinoma. Int J Cancer. 1994; 58: 825-829. (Pubitemid 2136664)
50. Badjatia N, Satyam A, Singh P, et al. Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. Urol Oncol. 2009 Jan 24. [Epub ahead of print].
51. Cameron E, Pauling L, Leibovitz B. Ascorbic acid and cancer: a review. Cancer Res.1979; 39: 663-681.
52. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1976; 73: 3685-3689. (Pubitemid 9028392)
53. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer, reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1978; 75: 4538-4542. (Pubitemid 9028392)
54. Buettner GR, Jurkiewicz BA. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res. 1996; 145: 532-541.
55. Hewitson KS, McNeill LA, Elkins JM, et al. The role of iron and 2-oxo-glutarate oxygenases in signalling. Biochem Soc Trans. 2003; 31: 510-515.
56. Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet 2004; 20: 33-43. (Pubitemid 38032818)
57. Sedgwick B. Repairing DNA-methylation damage. Nat Rev Mol Cell Biol. 2004; 5: 148-157.
58. Liang D, Lin J, Grossman HB, et al. Plasma vitamins E and A and risk of bladder cancer: a case-control analysis. Cancer Causes Control. 2008; 19: 981-992.
59. Israel K, Sanders BG, Kline K. RRR-alpha-tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutr Cancer. 1995; 24: 161-169.
60. Aggarwal S, Subberwal M, Kumar S, et al. Brain tumor and role of β-carotene, α-tocopherol, superoxide dismutase and glutathione peroxidase. J Cancer Res Ther. 2006; 2: 24-27. (Pubitemid 43254000)